Analysts have clear opinions on AIMT.

There are 7 analysts on the Wall offering 12 month price targets for Aimmune Therapeutics in the last 3 months. The average price target is $50.71 with a high forecast of $79.00 and a low forecast of $27.00. The average price target represents a 60.53% increase from the last price of $31.59.
Aimmune Therapeutics, Inc. (AIMT) is followed by 7 analysts on the street.

Liana Moussatos from Wedbush rates it a Buy with a target of $79.00.

Similarly, 24 days ago Christopher Raymond of Piper Jaffray Reiterated a Buy with a target of $60.00.

The consensus on the street is Moderate Buy.

What does Aimmune Therapeutics, Inc.(AIMT) do ?
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Aimmune Therapeutics, Inc. (AIMT) Insider Trades

Multiple company employees have indulged in significant insider trading. Aimmune Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Chief Medical Officer, Adelman Daniel C Md : S – Sale+OE(-$600,716) of AIMT in the trading session of 2019-12-09.

CFO Bjerkholt Eric : P – Purchase(+$34,977) of AIMT in the trading session of 2019-09-18.

GM, Europe Barrowcliffe Susan E. : S – Sale+OE(-$1,201,600) of Aimmune Therapeutics, Inc. in the trading session of 2018-11-19.

Looking for stocks just like AIMT?

Based on Wall Street analyst research, several stocks are similar to AIMT
They are:
– ADMP [Info can be found here: ]
– DBVT [Info can be found here: ]
– ADM [Info can be found here: ]